*Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology

Doran, W., Tunnicliffe, L., Muzambi, R., Rentsch, C. T., Bhaskaran, K., Smeeth, L., et al. (2024). Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records. Bmj Open Diabetes Res Care, 12. http://doi.org/10.1136/bmjdrc-2023-003548
Morgan, C. L., Durand, A., McCormack, T., Hughes, E., Berni, T. R., & Lahoz, R. (2023). Risk of major adverse cardiovascular events associated with elevated low-density lipoprotein cholesterol in a population with atherosclerotic cardiovascular disease with and without type 2 diabetes: a UK database analysis using the CPRD. Bmj Open, 13, e064541. http://doi.org/10.1136/bmjopen-2022-064541
Jeffery, A., Bhanu, C., Walters, K., Wong, I. C., Osborn, D., & Hayes, J. F. (2023). Polypharmacy and antidepressant acceptability in comorbid depression and type 2 diabetes: a cohort study using UK primary care data. Br J Gen Pract, 73, e392-e398. http://doi.org/10.3399/bjgp.2022.0295
Cook, S., Schmedt, N., Broughton, J., Kalra, P. A., Tomlinson, L. A., & Quint, J. K. (2023). Characterising the burden of chronic kidney disease among people with type 2 diabetes in England: a cohort study using the Clinical Practice Research Datalink. Bmj Open, 13, e065927. http://doi.org/10.1136/bmjopen-2022-065927
Birkeland, K. I., Bodegard, J., Banerjee, A., Kim, D. J., Norhammar, A., Eriksson, J. W., et al. (2021). Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes Obes Metab, 23, 75-85. http://doi.org/10.1111/dom.14189